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Abstract 
Objective: To explore care experiences of women who used prescription or illicit opioids and 
experienced fetal or infant loss. 
Design: A qualitative descriptive design with secondary data analysis. 
Setting: The Fetal and Infant Mortality Review in an urban Midwest county in the United States. 
Participants: Eleven women with histories of prescription or illicit opioid use who experienced 
fetal or infant loss participated in the semi-structured telephone or in-person interview portion of 
the mortality case review.  
Methods: Thematic analysis was used to analyze interview data. 
Results: Five themes were identified related to the care experiences of participants throughout 
pregnancy and fetal/infant loss: Frustration and anger related to not being heard, feeling 
minimalized; Being overwhelmed with attempts to process and understand medical 
complications and outcomes; Profound sense of grief and coping with loss; Need to understand 
why and make difficult decisions; Placing blame and guilt over death. 
Conclusions: Our findings suggest that women who use opioids and experience fetal/infant loss 
have complex care, educational, and emotional needs. When developing interventions for these 
women, it is important to address their unique and complex circumstances. 
Keywords: maternal narcotic use, maternal opioid use, perinatal bereavement, infant loss, 
prenatal care 
Call Outs 
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1) Opioid dependence presents serious health risks for pregnant women and their infants
including potential fetal/neonatal death.
2) Women who are dependent on opioids and experience fetal/infant loss have multiple
medical and behavioral health issues and often reported that care providers minimized
their concerns.
3) Interdisciplinary care, skillful communication, and patient-centered care are needed for
women with histories of opioid use who experience fetal/infant loss.
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Use of prescription and illicit opioids in the United States has increased significantly in 
the past 10 years (Ailes et al., 2015; Patrick, Kaplan, Passarella, Davis, & Lorch, 2014; Tolia et 
al., 2015). This increase has created a public health crisis of increased opioid dependence and 
addiction, drug overdose, and corresponding infectious disease (Degenhardt & Hall, 2012; Jones, 
Mack, & Paulozzi, 2013; Paulozzi, 2006; Roy et al., 2011). Opioid dependence during pregnancy 
presents unique perinatal health risks for women and their infants, including intrauterine fetal 
demise, low birthweight, preterm labor, and fetal and infant loss (Goettler & Tschudin, 2011; 
Pinto et al., 2010; Whiteman et al., 2014). Women who use opioids during pregnancy have 
complex needs, including addiction therapy, behavioral evaluation and treatment, and social 
support that are frequently not available through conventional prenatal care approaches (Jones et 
al., 2013; Jones & Kaltenbach, 2013; Winklbaur, Kopf, Ebner, Jung, Thau, & Fischer, 2008). 
Although coordinated care is critical for these women, little is known about care needs from the 
women’s perspectives. The purpose of our qualitative study was to explore care experiences of 
women who used opioids throughout pregnancy and experienced fetal or infant loss.  
{Insert Callout #1} 
Literature Review 
Needs for Prenatal and Drug Treatment Care 
From 2000 to 2009, the prevalence of opioid use in the prenatal period increased five-
fold from 1.2 to 5.6 per 1,000 live births (Patrick, Davis, Lehmann, & Cooper, 2015). Compared 
to the general population, women who use opioids have higher rates of preterm birth (25% vs. 
9.6%), low birth weight (31% vs. 5-8%), and intrauterine growth restriction (30% vs. 8% (Pinto 
et al., 2010).  In response to the rapid increase in the use and abuse of opioids, the federal 
government passed the Protecting Our Infants Act of 2015. This legislation directed agencies to 
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develop strategies to prevent and treat  opioid use during pregnancy and neonatal abstinence 
syndrome (NAS) by assessing the comprehensive health care needs of women who use opioids 
during pregnancy and the long-term consequences of prenatal opioid exposure on infants (Miller 
et al., 2016; Ruble, 2016). The American College of Obstetricians and Gynecologists (ACOG, 
2012) has developed policy statements and clinical care recommendations to improve prenatal 
care, substance abuse treatment availability and accessibility, and reduce NAS. Prenatal care for 
women who use opioids includes assessment of substance use history; referral to tertiary 
obstetric services or drug treatment specialists; opioid substitution therapy during antenatal, 
birth, and postpartum stages; and management of relapse (Abrahams, Chase, Desmoulin, 
Roukema, & Uddin, 2012; Arunogiri, Foo, Frei, & Lubman, 2013; Winklbaur et al., 2008).  
Opioid use remains one of the most common reasons why women do not seek early 
prenatal care (Friedman, Heneghan, & Rosenthal, 2009; Schempf & Strobino, 2009). The stigma 
attached to the use of drugs during pregnancy could be a barrier. Public discourse and media 
attention have focused on the dangers of fetal exposure without taking into account the history of 
each woman (Kennedy-Hendricks, McGinty, & Barry, 2016).  Also, the complex physical, 
psychological, and social needs of this population make it difficult to design appropriate, 
comprehensive, and coordinated care. Women who use opioids during pregnancy are at higher 
risk for perinatal complications and require high-risk pregnancy services. They have additional 
needs for substance abuse treatment, chronic pain treatment, behavioral health services, and 
social support.  
Attitudes of care providers toward pregnant women who use opioids may also deter the 
women from seeking care. Goodman and Wolff (2013) found that 46% to 95% of physicians 
believed that drug or alcohol use during pregnancy is a form of child abuse and favored 
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compulsory treatment for the women. However, drug treatment, such as opioid substitution 
therapy (OST), may not always be viewed by women as helpful. Chandler et al. (2013) found 
that some women perceived OST as a barrier to normal family life because substitute drugs (e.g., 
methadone) gave them “a kind of fuzzy feeling” and drug treatment required frequent trips to 
care centers and disclosure of their drug histories to more people. As suggested by Jones et al. 
(2008) advancing an evidence-based approach to optimal care for women with opioid use is 
possible only when we know more about the needs of opioid-dependent pregnant women. 
Transition to Motherhood: Care and Support for Women Who Use Opioids  
In the Transitions Framework, Meleis (2000) described pregnancy, childbirth, and 
parenthood as lifespan transition and emphasized that a healthy transition enables an individual 
to feel connected, to better interact with others, and develop confidence and coping strategies. 
While many women easily transition to motherhood, women who use opioids may be challenged 
in this transition by difficulty in developing the maternal-infant relationship, custody loss, or 
death of the infant. Prenatal opioid use was associated with insecurity in attachment to the infant, 
re-hospitalization, and child abuse and neglect (Foulkes, 2015; Friedman et al., 2009; Patrick & 
Wu, 2015; Terplan, Kennedy-Hendricks, & Chisolm, 2015; Worcel, Furrer, Green, Burrus, & 
Finigan, 2008). Mothers who use drugs may be less sensitive to infant cues and have inadequate 
infant care knowledge and skills. Removing an infant from a mother who uses opioids and 
placing the infant in a different family environment is often done to offer protection to the infant 
(Smith, Johnson, Pears, Fisher, & DeGarmo, 2007; Young, Boles, & Otero, 2007). However, this 
course of action could be viewed by the mother as punitive and can be detrimental to the 
mother’s recovery and treatment compliance (Krans & Patrick, 2016; Ordean, Kahan, Graves, 
Abrahams, & Kim, 2015; Stone, 2015; Worcel, 2008). Nevertheless, loss of parental rights or 
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custody is common for mothers who use drugs and constitutes an  involuntary loss which can 
cause a grief response with persistent anger, and could result in the need to blame others to 
minimize the consequences attributable to substance abuse and allow the mother to manage guilt 
and maintain her maternal identity (Sykes, 2011; Wells, 2011). 
Another type of loss experienced by mothers who use opioids is perinatal or infant death. 
Women who abuse substances are 3-4 times more likely to experience fetal or infant death than 
the general population (King-Hele et al., 2009). Potential complications of opioid use that 
increase these risks are intrauterine growth restriction, premature labor, placental abruption, and 
sudden unexplained infant death (Jones, H. 2013a; Whiteman, 2014). Research on the perinatal 
or infant death experiences of mothers who use opioids is limited. Fetal and infant loss or death 
was described as a painful and traumatic experience for all mothers during their transitions to 
motherhood (Gaudet, 2010; Kersting, 2012; Rubin, 1985; Rubin & Malkinson, 2001). Mothers 
with such loss experience numbness, yearning, disorientation, and despair (Badenhorst, & 
Hughes, 2007; Bennett, 2005). Unresolved grief reactions may contribute to initial addiction or 
relapse of substance abuse, and addiction can also hinder the resolution of the grieving process in 
subsequent losses (Denny, 1984; Smith, 2009).  
Substance use is a potential complication of the grief experience as bereaved mothers 
have as much as a two-fold increase in the need for hospitalization due to substance use over 
mothers who have not experienced a loss (Li, Laursen, Precht, Olsen, & Mortensen, 2005; 
Zuckoff et al., 2006). Some mothers seek to maintain relationships with their deceased children 
by carrying photographs and observing anniversaries; others may withhold emotional attachment 
in subsequent pregnancies until the perceived threat of loss is resolved (Lewis, 2006). Even 
though rates of perinatal loss are increased with maternal opioid use and the number of women 
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who use opioids during pregnancy is increasing, there is little information in current literature 
about the unique aspects of these mothers’ experiences. Our study, which was based on Fetal and 
Infant Mortality Review (FIMR) maternal interviews, was designed to explore the care 
experiences of women who used prescribed or illicit opioids during pregnancy and had fetal or 
infant loss.   
Methods 
Design 
We conducted a thematic analysis (Sandelowski, 2000; Vaismoradi, 2013) of qualitative 
maternal interview data from a FIMR program in a Midwest County Department of Public 
Health in the United States. Our study was approved by the Institutional Review Board of 
Indiana University. Only de-identified FIMR data were used and were stored in a password 
protected drive used specifically for research data. 
Participants 
 Inclusion criteria required participants to be age 18 or older with known histories of 
prenatal opioid use and fetal or infant losses. Between the years 2007 and 2012, the local FIMR 
program reviewed a total of 381 infant mortality cases; 194 (51%) of the mothers participated in 
interviews. In the same period, 26 adult mothers experienced a fetal or infant losses and were 
also identified as opioid users (prescribed or illicit). Of the 26 women, 11 (42.3%) participated in 
a semi-structured telephone or in-person interview. Data from the 11 interviews were analyzed in 
this study. Interviews were conducted 3.5 – 10 months after the fetal/neonatal death (average = 
5.2 months). Nine participants were interviewed by five months after infant death.  
Data Collection 
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The 11 interviews were conducted by four FIMR program nurses who received the 
National FIMR Maternal Interview Training on how to conduct an interview, comply with public 
health and safety codes, and handle difficult encounters. Interview questions asked of each 
participant focused on their thoughts and perceptions of the care they and their infants received 
and their experiences throughout the pregnancy and loss (See Table 1). Interviewers took 
detailed written notes during the interviews. Audio or video recordings were not used in the 
interviews because of the sensitive nature of the subject. The interview notes were typed and 
saved in a FIMR database. 
Data Analysis 
Coding and thematic analysis were conducted in three phases using the thematic analysis 
process described by Vaismoradi (2013). The first author is a neonatal nurse practitioner and a 
Ph.D. student with experience in treating infants with NAS. The second author is a prenatal 
health behavior researcher with experience in qualitative data analysis. In the first phase, to 
familiarize ourselves with the data, the first two authors read interview documents several times 
along with abstracted medical, obstetric, and infant data. The second phase of data analysis 
consisted of organizing data, including generating initial codes, searching for themes, and 
reviewing and naming themes. Interview data were initially organized based on the experience of 
pregnancy, birth, and postpartum periods (including care of the newborn), and infant care (up to 
1 year). First, the two authors coded interviews independently; codes with similar meaning were 
grouped into themes within each perinatal stage. Then, we met in person to resolve coding and 
theme naming discrepancies. In the third phase of analysis, two additional authors reviewed 
codes and themes: a neonatologist with experience in qualitative research and the FIMR process 
and the coordinator of the local FIMR program. These two team members verified whether they 
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could follow the analysis processes (dependability) and commented on whether the themes in 
each stage were meaningful to individuals in clinical and public health practice (transferability). 
Discrepancies in this phase were resolved by group discussion via email. Data saturation was 
reached in each theme.  
Results 
Participants 
The sample consisted of 11 participants (Table 2). The participants ranged in age from 18 
to 36 years. Most were White (n = 8), single (n = 9), and with less than high school educations (n 
= 7). Nine participants used opioids exclusively, and two reported or tested positive for 
polysubstance abuse. Four participants used prescription opioids for chronic pain, one participant 
was in a drug rehabilitation program using methadone, and five participants used opioids illicitly. 
Three deaths occurred before birth (intrauterine fetal demise), three during the neonatal period 
(first month after birth), and the remaining five in infancy (one month to one year after birth). 
Six deaths were related to prematurity or congenital/genetic abnormalities, and five were caused 
by sudden unexpected death, pneumonia, placental abruption, or unknown causes. 
{Insert Callout #2} 
Themes  
Five themes were identified that represented the experiences of participants. The themes 
were: frustration and anger related to not being heard, feeling minimalized, being overwhelmed 
with attempts to process and understand medical complications and outcomes, profound sense of 
grief and coping with loss, need to understand why and make difficult decisions, placing blame 
and guilt over death.    
Frustration and anger related to not being heard, feeling minimalized 
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Many participants voiced their frustration that care providers did not listen to their 
concerns during pregnancy or the infant’s illness. They wanted care providers to value their input 
and experiences. They also wanted care providers to “listen to” and “pay attention to” them:  
“My baby could have been saved if my prenatal doctor would’ve listened to me and paid 
attention to me.” “I think if they looked more into what I was going through my loss could have 
been prevented.” 
“I took her to the clinic multiple times…and the doctors kept saying she was fine and not 
to worry about it. Then in May, I took her to get her shots and the next thing I know she’s 
dead.” 
Some participants stated that providers did not ask what they wanted regarding their 
infant’s care. Some participants felt they knew something was wrong, but care providers did not 
listen to their concerns: “I knew something was wrong. They never listened to me. They were all 
against me, and never asked what I wanted.” “If my prenatal doctor would've listened to me and 
paid attention to my extremely high blood pressure; took my son… when I begged her to because 
I had pre-eclampsia and my son's heartbeat was only 118.” 
Some participants felt “upset” because they were not adequately informed about 
complications and medical treatment. They were not allowed to fully participate in care 
decisions. If explanations were offered, they did not facilitate the participant’s understanding. 
The lack of information and communication frustrated the participants and contributed to their 
feelings of being ignored and marginalized in making care decisions: 
“Everything was going okay, not great, but okay. Then one day they told me that 
they removed the breathing tube, without my permission. He didn’t like it, and 
they had to put it back in. When they put it back in, they punctured a lung and 
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messed everything up. We had no idea what was going on, and all of sudden they 
handed me my son and said he was dead. I called the father, he was driving home 
from work, and I told him I was holding our dead baby. We had no idea what 
happened. I was so upset. I needed to get out of there.” 
Being overwhelmed with attempts to process and understand medical complications and 
outcomes 
Some participants had preexisting medical problems (e.g., hypertension, obesity, sexually 
transmitted infection, hypothyroidism, sickle cell trait) and pregnancy complications, such as 
vaginal bleeding, placental insufficiency, or chorioamnionitis. Some participants also reported 
behavioral health issues such as bipolar disorder, anxiety, depression, and schizophrenia. These 
medical and behavioral comorbidities added complexity to their prenatal care and often required 
referrals. “I went from jail to the mental hospital, and they put me on a medication called 
Lurasidone that killed my baby. With my other children, I wasn’t taking no medication, and 
nothing like that happened.” “My OB saw me while I was in the hospital and decided to transfer 
me to another hospital because they didn’t know what else to do. I had two blood transfusions, 
and they stopped the magnesium.” 
  It was sometimes difficult for participants to identify physical signs of complications 
such as preterm labor. Some were seen and evaluated and sent home. As a result,  they did not 
know whether they were actually in labor when the pain recurred. “I was having pains in my side 
and didn’t realize I was having contractions until I got to the hospital.” “I stayed home until the 
pain became unbearable and then went back to the hospital.” 
Other complications during pregnancy were also common in the participants. Thoughts 
about hemorrhage, placental problems, and pregnancy-induced hypertension worried some 
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mothers and increased their anxiety levels. The participants reported being anxious about their 
treatment, being transferred to another hospital, being told of the need for a cesarean birth, and 
uncertainty of the baby’s survival. “She was born two weeks before that time she could live. Her 
heart and lungs were underdeveloped. They said she might make it and might not.” “I went to the 
hospital and was bleeding everywhere. Pool of blood. They said my daughter swallowed it.” 
Profound sense of grief and coping with loss 
Participants struggled to deal with grief. They expressed “how lost I feel about losing 
him” and “this is a very hard thing to go through.” Some participants wished “there was 
something you can do” to bring back their infants. Others thanked God for having other children 
who were alive. “Do you know how hard it is to deal with this after having him inside you all 
these months and then touching his hands and feet? This has been the worst 5 months of my 
life.” “That is a very hard thing to go through, and you still wish there was something you could 
do.” “…just how lost I feel about losing him and how lost I am without him! I just thank God for 
my other sons.” 
Participants talked about the support they received during the experience with grief. 
Some expressed appreciation for bereavement services, such as booklets on bereavement, molds 
of handprints and footprints, or photographs. Others experienced frustration and disappointment 
because they did not receive enough support or resources. Participants also expressed receiving 
various degrees of professional bereavement support. Some had begun counseling with a 
psychiatrist or were considering grief support groups. “Everyone at the hospital was excellent. 
They made molds [of my baby’s hands and feet]. I was worried that I couldn’t afford to bury her, 
so they let me talk to the trustee.” 
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“I am seeing [a] psychiatrist right now for my grief. I think it is helping. I am not ready to 
talk to people about it in a group or talk to other people. It’s just too hard, and I am not 
ready.” 
Some participants had difficulty managing their grief and others actively made plans for 
closure through a “memorial service” for their baby, spirituality, and family support. They 
sought validation for their feelings of grief and loss but sometimes felt pushed by family and 
friends to move on. “We had a memorial service for him and buried him at the cemetery…We 
are doing okay with the loss; we have a lot of family.” “Can I ask you something? People tell me 
the more I talk about her, or keep wanting to celebrate her birthday; I will never get over her 
…Do you think it is okay to celebrate her birthday?” 
Need to understand why and make difficult decisions 
Participants expressed that they were adept at recognizing changes in their infant’s health 
status (e.g., coughing and throwing up or not breathing) particularly after hospital discharge. 
They sought medical attention and explanations. However, there were times some participants 
had to make difficult decision about care and treatment. “My baby did good at first. When he 
was 3 and half or 4 months old I noticed he couldn’t open his hand or sit up straight.” “I took her 
to the hospital and clinic multiple times because she was coughing and throwing up.” “I called 
out for someone to call 911 and started CPR, but it was already too late.” “His father and I 
decided to take him off the machine.” 
 Participants wanted to understand and make sense of their infant’s death. Knowing how 
and why their infant died seemed to offer them a “closure.” Knowing the cause of infant death 
was also important for them to understand implications for future children. They also wanted 
reassurance that their care, as a parent, and the health care provided was sufficient as “they did 
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what they could for her [infant].” “Well, at least now we have closure. I wish someone had told 
us sooner; we have been going nuts not knowing.” “Now I know he did die because of sleep 
apnea.” “They said she had a tube defect and it was an encephalocele, and she couldn’t live.” “I 
don’t remember the name of the condition he had, but the doctors said it was genetic.” 
Placing blame and guilt over death 
Participants responded to infant death with two reactions. Some blamed health care 
providers because “they are responsible for her [infant] death.” Others blamed themselves for the 
infant’s death and believed that if they had done something to help the baby, the death would not 
have occurred.  “I believe the OB doctors should be checked out. My baby could have been saved 
…” “I wanted to sue the hospital and clinic because they are responsible for her death.” 
At times, pressure from family and friends precipitated feelings of self-blame and guilt. 
Occasionally, participants turned the blame to themselves and searched for how they might have 
prevented the death. “If we had used the monitor he might be alive. I wish we had kept on using 
the machine anyway.” “When I woke up, I knew something was wrong. I freaked out. So I told 
everyone she dies in her crib. But she was in bed with me. I tell everyone I know, see with a 
baby, everyone- not to sleep with their baby.” “All my friends and family thought I killed my 
baby. They kept saying I smothered her and stuff. My mom was real angry, but she was also 
crying.” 
Discussion 
Our results indicate that women who used opioids and experienced infant/fetal loss had  
complex needs which were often  unmet. Of note, participants in our study repeatedly voiced 
concerns about not being heard, being ignored, and being undervalued. These concerns may be 
related to the stigma of addiction; however, it is also likely that they may have been exacerbated 
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by participants’ anxiety about their high-risk conditions and frequent urgent medical treatments. 
The perception that their feelings were minimalized could also reflect their frustration and 
helplessness over the deaths of their infants. In previous studies on addiction, women expressed 
feelings of stigmatization from family, friends, society, and health care providers (Chandler et 
al., 2013; Earnshaw, Smith, & Copenhaver, 2013; McGinty, Goldman, Pescosolido, & Barry, 
2015). If allowed to develop, these perceptions of stigma can create a lack of trust in individual 
health care providers and the health care system and serve as barriers to accessing care (Casper 
& Arbour, 2013; Winklbaur et al., 2008).  
Many participants in our study had difficulty understanding why devastating medical 
complications occurred for them and their infants and often felt the communication from health 
care providers was inadequate, incomplete, or difficult to understand. This problem of 
incomplete understanding may be caused partially by the stress and uncertainty of the situation 
itself, but also may reflect a lack of communication skills among health care providers (Pozzo, 
Brusati, & Cetin, 2010). Several previous studies conducted with patient populations facing high 
stress and complex medical situations, such as cancer or high-risk pregnancy, have indicated the 
need for standard protocols and practice in delivering bad news (Pozzo et al., 2010). In the 
context of maternal opioid users experiencing fetal and infant complications, providers could 
also be helped in their regular communication by training on how to deal with the mothers’ 
emotional reactions and the mother’s need to be well informed. Communication would be 
enhanced if health care providers created illustrations and provided information in clear and 
simple terms. Mothers who report satisfaction with the information they receive are better 
prepared to take action and make good decisions (Makary, 2015).  
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Dealing with grief, guilt, and blame was an ongoing process for participants from the first 
time infant complications were identified through the infant’s death and months later. Although 
every mother grieves in her own way, lack of support may prolong grief (Badenhorst, 2007; 
Cacciatore, Schnebly, & Froen, 2009; Kersting & Wagner, 2012). Moreover, the perinatal loss 
can be a trigger for addiction relapse (Smith, 2009). Bereavement support can help mothers with 
fetal/infant loss acknowledge their feelings of guilt over blame and the added burden of 
stigmatizing addiction (Bennett, Litz, Lee, & Maguen, 2005; Murphy, Shevlin, & Elklit, 2014).  
Anger and blame towards others, or self is a typical reaction after a perinatal loss, 
particularly when mothers feel unsupported or uninformed (Badenhorst, 2007; McCright, 2008; 
Cacciatore, Frøen, & Killian, 2013). Providers need to recognize that grief may be expressed in 
many ways, including blaming others. Blame is a normal aspect of grief in perinatal loss and 
many mothers blame themselves for their loss which may be a barrier to resolution of grief 
(Cacciatore, 2013). However, our participants turned blame toward themselves with less 
frequency than in general perinatal grief studies (Badenhurst, 2007; Kersting, 2012)). Blaming 
others may represent an abnormal grief reaction related to the need to minimize implications of 
substance use. Regardless of the reason, providing support and counseling is essential. 
Limitations 
The use of secondary data analysis provided only a narrow window into the care 
experience of the mothers. The FIMR interview was constructed for a specific purpose of 
identifying multiple maternal and infant healthcare, social, and community service issues. We 
were unable to clarify participants’ care experience with additional interview questions. We were 
also unable to explore specific care experiences regarding methadone use or other drug treatment 
during pregnancy. The interviews were not recorded on audio or visual media. Although 
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extensive written notes were completed based on the FIMR protocols, written notes might not 
have captured all information given by each interviewed mother. The range of time between the 
loss and the interview (3.5 to 10 months) is also a possible limitation. Grief is an individual 
experience and mothers interviewed soon after their infant’s death may report a very different 
experience than those interviewed several months later.  Unique perspectives related to opioid 
use and dependence may also affect the grief experience.  
The secondary data analysis also prevented us from conducting member checks. Member 
checks reviewing the themes identified with the participants would have helped validate our 
findings. Our study was limited to a small number of women in one local FIMR program. 
Further study is needed to determine whether our findings are similar to those from other women 
with opioid use who experience a fetal/neonatal loss.  
Implications for Practice 
Our findings indicated that health care providers need to partner with women who use 
opioids designing care and making treatment decisions that acknowledge their needs, 
perceptions, and satisfaction (Wolf, Lehman, Quinlin, Zullo, & Hoffman, 2008). Such a 
partnership fosters respect, shared decision making, and a caring environment where the 
concerns of mothers who use opioids can be addressed. This partnership focus also encourages 
care providers to be sensitive to the needs of these women to help reduce the perception of 
stigmatization and increase the perception of being valued.   
The need for health care provider education and training in effective and sensitive 
communication is evident from this study. The participants’ perception was that caregivers who 
did not listen to them, minimized their  feelings, and were unsupportive, contributed to their 
pain, guilt, and bereavement experience. Projecting acceptance, accessibility, and readiness to 
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listen is essential, as well as providing understandable medical information about the care 
provided and procedures performed (Fleischer, Berg, Zimmermann, Wüste, & Behrens, 2009). It 
is important to understand communication is bidirectional and the patient’s interpretation of the 
message may be very different than the nurse’s or other provider’s intended message (Kourkouta 
& Papathanasiou, 2014). It is also necessary to continually assess the mother’s knowledge and 
confirm understanding of health information given. 
Comprehensive multidisciplinary care models may provide opportunities for care 
providers from different disciplines to develop coordinated care plans for opioid-using mothers 
and their infants, as well as to enhance communication among care providers. Continuing 
education programs or conferences could emphasize multidisciplinary aspects of care for the 
mothers with opioid use. 
Bereavement support and counseling is particularly important for the mothers who use 
opioids and experience perinatal or infant death. Such support and counseling may need to be 
long-term in order to resolve the mothers’ reactions of guilt, anger, and blame. There is a need to 
improve patient-provider communication and to address both individual and systems failures 
which may lead to poor outcomes through formal review processes such as FIMR and Child 
Death Review programs. 
{Insert Callout #3}  
Recommendations for Future Research 
Further exploration of this topic could best be accomplished with a phenomenology 
approach using open-ended interviews. This would provide a richer and more complete 
description of the participants’ experience. More focused exploration divided by the timeframe 
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of the loss (fetal, neonatal, or infant) may also aid in theory development, as well further 
defining guidelines for effective practice.   
Conclusions 
The rapid increase in opioid use among pregnant women has led federal agencies to 
demand more research to determine best practice for caring for affected women and infants. We 
examined the care experiences of women who used opioids throughout pregnancy and 
experienced fetal or infant loss. Five themes were identified: not being heard, or feeling 
minimalized, being overwhelmed with attempts to process and understand medical complications 
and outcomes, a profound sense of grief and coping with loss, a need to understand why and 
make difficult decisions, a need to place blame and assign guilt over death. The study findings 
suggest interdisciplinary team care, partnership in decisions, provider training for skillful 
communication, and emotional support for mothers with opioid use and pregnancy or infant loss. 
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Table 1: Fetal Infant Mortality Review (FIMR) Case Study Suggested Interview Questions 
Prenatal, Labor, and Delivery Infant’s Death 
Please tell me about the last few days of your 
pregnancy, your labor, and when your baby 
was born. 
How was your baby’s death explained to you? 
How satisfied were you with the prenatal care 
you received? 
What is your understanding of your baby’s 
death? 
 Share what happened after your baby’s death. 
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Table 2: Demographics, Drug Use History, and Obstetric History for Study Participants (N = 11) 
 
Variables n (%) Variables n (%) 
Age (years), Mean (SD) 
Range: 18 - 36 
 
25 (7.27) 
 
Number of Pregnancies, Mean (SD) 
Range: 1 - 6 
 
3.45 (1.97) 
 
 
Ethnicity 
    African American 
    White 
 
3 (18) 
8 (72) 
First Pregnancy 
    No 
    Yes 
 
10 (77) 
3 (23) 
Education 
   Less than high school 
   High school 
   Master/PhD 
 
 
7 (64) 
2 (18) 
2 (18) 
 
Timing of Perinatal/Infant Death                   
    Fetal stage 
    Neonatal stage 
    Infant stage 
  
3 (27) 
3 (27) 
5 (45) 
 
Marital Status  
    Married  
    Single  
   
 
 
2 (18) 
9 (82) 
 
 
This Pregnancy Planned 
    No 
    Yes 
    Unknown 
 
  
4(36) 
3 (27) 
4 (36) 
Tobacco Use 
   Yes 
   No 
   Unknown 
 
8 (73) 
2 (18) 
1 (9) 
Health Insurance 
    Medicaid 
    Private 
    None 
     
 
9 (82) 
1 (9) 
1 (9) 
  
Maternal Opioid Use 
Prescription (1 
methadone treatment) 
    Illicit 
 
 
 
 
 
 
6 (55) 
 
5 (45) 
 
 
 
 
 
Reasons for Fetal/Infant Death 
    Prematurity 
    Congenital Anomalies 
    SUIDS/ Suffocation/Apnea 
    Genetic Syndrome 
    Pneumonia 
    IUFD (abruption) 
    Unknown 
 
 
4 (36) 
1 (9) 
2 (18) 
1 (9) 
1 (9) 
1 (9) 
1 (9) 
 
Note. IUDF: intrauterine fetal demise; SUIDS: sudden unexpected infant death.  
 
 
